DIRS.INFO The most relevant business & tech news

The Major Supreme Court Cases of 2024No Supreme Court term in recent memory has featured so many cases with the potential to transform American society. In 2015, the Supreme Court limited the sweep of the statute at issue in the case, the Sarbanes-Oxley Act of 2002. In 2023, the Supreme Court temporarily blocked efforts to severely curb access to the pill, mifepristone, as an appeal moved forward. A series of Supreme Court decisions say that making race the predominant factor in drawing voting districts violates the Constitution. The difference matters because the Supreme Court has said that only racial gerrymandering may be challenged in federal court under the Constitution.

Persons: Donald J, Trump, Anderson, Sotomayor Jackson Kagan, Roberts Kavanaugh Barrett Gorsuch Alito Thomas, Salmon, “, ”, Mr, Nixon, Richard M, privilege.But, Fitzgerald, Vance, John G, Roberts, Fischer, Ruth Bader Ginsburg, Clarence Thomas, Samuel A, Alito Jr, Alito, ’, Moyle, Wade, Roe, Johnson, Robinson, Moody, Paxton, Robins, Media Murthy, Sullivan, Murthy, Biden, Harrington, Sackler, Alexander, Jan, Raimondo, ” Paul D, Clement, Dodd, Frank, Homer, Cargill Organizations: Harvard, Stanford, University of Texas, Trump, Liberal, Sotomayor Jackson Kagan Conservative, Colorado, Former, Trump v . United, United, Sarbanes, Oxley, U.S, Capitol, Drug Administration, Alliance, Hippocratic, Jackson, Health, Supreme, Labor, New York, Homeless, Miami Herald, Media, Biden, National Rifle Association, Rifle Association of America, New York State, Purdue Pharma, . South Carolina State Conference of, Federal, Loper Bright Enterprises, . Department of Commerce, Chevron, Natural Resources Defense, ”, SCOTUSPoll, Consumer Financial, Community Financial Services Association of America, Securities, Exchange Commission, Exchange, Occupational Safety, Commission, Lucia v . Securities, Federal Trade Commission, Internal Revenue Service, Environmental Protection Agency, Social Security Administration, National Labor Relations Board, Air Pollution Ohio, Environmental, Guns Garland, Alcohol, Tobacco, Firearms, Explosives, National Firearms, Gun Control Locations: Colorado, Trump v . United States, United States, Nixon, Florida, Gulf of Mexico, Dobbs v, Idaho, Roe, Texas, States, New, New York, Grants, Oregon, . California, Martin v, Boise, Boise , Idaho, Missouri, Parkland, Fla, Murthy v . Missouri, . Missouri, ., South Carolina, Alabama, SCOTUSPoll, Lucia v, Western

☆ National Sciences Academy Asks Court to Strip Sackler Name From Endowment
▼ + stars: | 2024-04-12 | by ( Christina Jewett | ) www.nytimes.com time to read: +1 min

The National Academy of Sciences is asking a court to allow it to repurpose about $30 million in donations from the wealthy Sackler family, who controlled the company at the center of the opioid epidemic, and to remove the family name from the endowment funds. The petition filed by the Academy in Superior Court in Washington, D.C., Thursday aims to modify the terms of the donations so the institution can use them for scientific studies, projects and educational activities. The move follows a report in The New York Times last year that examined donations from several Sackler members, including an executive of Purdue Pharma, which produced the painkiller OxyContin that has long been blamed for fueling the opioid crisis that has claimed thousands of lives. “The notoriety of the Sackler name has made it impossible for the Academy to carry out the purposes for which it originally accepted the funds,” Marcia McNutt, president of the National Academy of Sciences, said in a statement released on Thursday.

Persons: Sackler, ” Marcia McNutt Organizations: National Academy of Sciences, Academy, Washington , D.C, The New York Times, Sackler, Purdue Pharma Locations: Superior Court, Washington ,, The

☆ Institutions Are (Quietly) Taking Sackler Money
▼ + stars: | 2024-01-25 | by ( Alex Marshall | ) www.nytimes.com time to read: +1 min

When arts organizations began shunning the Sackler family over its role in the U.S. opioid crisis, it wasn’t just American institutions that cut ties. Museums in Britain that had accepted Sackler largess were among the first to take action. After the National Portrait Gallery in London canceled a $1.3 million Sackler donation in 2019, the Tate museum group announced it would not seek any more of the family’s support. Other museums began discussing removing the Sackler name from their walls. According to the Sackler Trust’s latest accounts, which were published this month, the nonprofit committed around 5.2 million pounds, or $6.6 million, in 2022, comprising 66 grants to institutions.

Persons: Sackler, — Organizations: Museums, Tate, Sackler Trust —, Purdue Pharma, Sackler Locations: U.S, Britain, London, British

☆ Supreme Court Weighs Purdue Pharma’s $6 Billion Opioid Settlement
▼ + stars: | 2023-12-05 | by ( Jess Bravin | ) www.wsj.com time to read: +1 min

Purdue Pharma headquarters in 2019; a Purdue lawyer said in court Monday that if a settlement with the company didn’t go forward, opioid-crisis victims might not see compensation. Photo: timothy a. clary/Agence France-Presse/Getty ImagesWASHINGTON—Supreme Court justices wrestled Monday with the uncomfortable bargain struck between most victims of the opioid crisis and the Sackler family, whose Purdue Pharma promoted the addictive painkiller OxyContin: providing timely compensation for survivors in exchange for granting the wealthy family immunity from future civil lawsuits. That settlement was reached before a bankruptcy judge and approved in May by a federal appeals court in New York. It would see the Sacklers pay $6 billion to individual victims and state governments in exchange for eliminating potential liability for additional claims, such as fraud—even though they, unlike Purdue, haven’t sought bankruptcy protection. The deal was made under a catchall provision of federal law authorizing bankruptcy judges to issue orders and judgments that may be “necessary or appropriate” to resolve cases.

Persons: timothy, clary, Sackler, haven’t Organizations: Purdue Pharma, Purdue, Agence France, Getty, WASHINGTON Locations: New York

At issue is whether U.S. bankruptcy law allows Purdue's restructuring to include legal protections for the members of the Sackler family, who have not filed for personal bankruptcy. Members of the Sackler family have denied wrongdoing but expressed regret that OxyContin "unexpectedly became part of an opioid crisis." They said in May that the bankruptcy settlement would provide "substantial resources for people and communities in need." The administration told the Supreme Court that Purdue's settlement is an abuse of bankruptcy protections meant for debtors in "financial distress," not people like the Sacklers. The administration has also alleged that the Sackler family members withdrew $11 billion from Purdue before agreeing to contribute $6 billion to its opioid settlement.

Persons: painkiller, George Frey, Joe Biden's, Sackler, Biden, OxyContin, John Kruzel, Andrew Chung, Will Dunham Organizations: Purdue Pharma L.D, REUTERS, Rights, Purdue Pharma, WASHINGTON, U.S, Supreme, Purdue, Circuit, Thomson Locations: Provo , Utah, U.S, Stamford , Connecticut, Manhattan

☆ Supreme Court to Hear Challenge to Controversial Purdue Pharma Deal
▼ + stars: | 2023-12-04 | by ( Abbie Vansickle | More About Abbie Vansickle | ) www.nytimes.com time to read: +1 min

Purdue Pharma and the wealthy family that controlled it are forever linked to the deadly opioid epidemic, which has left hundreds of thousands of people dead. But their role in the public health crisis is not the central question that the Supreme Court will wrestle with on Monday when it hears arguments over a bankruptcy settlement involving Purdue, the maker of the highly addictive painkiller OxyContin. Instead, the justices will focus on a narrower issue: whether the plan, devised to address the thousands of claims brought by state and local governments, tribes, hospitals and individual victims, can give wide-ranging legal protections to members of the Sackler family, the owners of the company. Under the deal, the Sacklers would pay up to $6 billion of their fortune toward settling those claims in exchange for immunity from all civil legal disputes related to the opioid crisis and Purdue.

Persons: Sackler Organizations: Purdue Pharma, Purdue

☆ The oxycontin-peddling Sackler family has tried to get immunity from civil lawsuits by filing for bankruptcy. That might be illegal.
▼ + stars: | 2023-12-03 | by ( Katie Balevic | ) www.businessinsider.com time to read: +3 min

The US Supreme Court will decide whether Purdue Pharma's bankruptcy settlement will stand. Officially referred to as third-party nonconsensual releases, the legal maneuver allows organizations to settle personal injury claims in bankruptcy court instead of civil court. Legal experts say companies are more often relying on bankruptcy court than civil court to settle claims, The New York Times reported. Opponents of the practice say it robs regular people of their day in civil court. The Sacklers' settlement deal did not require the Sacklers themselves to declare bankruptcy, just Purdue Pharma, according to the Times.

Persons: Sackler, — Organizations: Purdue, Service, Purdue Pharma, Reuters, The New York Times, Times

☆ At Core of Purdue Pharma Case: Who Can Get Immunity in Settlements?
▼ + stars: | 2023-12-03 | by ( Abbie Vansickle | More About Abbie Vansickle | ) www.nytimes.com time to read: +1 min

For years, Purdue Pharma, the maker of the prescription painkiller OxyContin, had been entangled in lawsuits seeking to hold it to account for its role in the spiraling opioid crisis. A pathbreaking settlement reached last year appeared to signal the end to thousands of those cases, funneling billions of dollars toward fighting the epidemic in exchange for exempting members of the billionaire Sackler family, which once controlled the company, from civil lawsuits. But on Monday, the Supreme Court will hear arguments over whether the agreement is a violation of federal law in a case that could have ramifications not just for Purdue but also for organizations that turn to bankruptcy court, as the company did, to resolve claims of mass injury. “There’s huge implications for all of corporate bankruptcy,” said Anthony J. Casey, a law professor at the University of Chicago. “I think this is probably the most important bankruptcy case before the court in 30, maybe 40 years.”

Persons: Sackler, “, ”, Anthony J, Casey Organizations: Purdue Pharma, Purdue, University of Chicago

Bottles of prescription painkiller OxyContin made by Purdue Pharma LP sit on a shelf at a local pharmacy in Provo, Utah, U.S., April 25, 2017. The settlements, which require a judge's approval, were disclosed in papers filed on Tuesday in federal court in San Francisco. The money is on top of $641.5 million that McKinsey already paid to resolve claims by state attorneys-general. McKinsey will pay $207 million to resolve claims by counties and municipalities, and another $23 million to resolve claims by public school districts. Aelish Baig, a lawyer for the local governments, in a statement called the deal "a strong outcome for the communities harmed by this crisis".

Persons: painkiller OxyContin, George Frey, Aelish Baig, McKinsey, Joe Biden's, Purdue Pharma's, Nate Raymond, Miral Organizations: Purdue Pharma, REUTERS, Companies Mckinsey, Company, Consulting, McKinsey, Co, U.S . Centers for Disease Control, U.S, Supreme, Purdue, Thomson Locations: Provo , Utah, U.S, San Francisco, United States, Boston

The settlement involving Purdue, the maker of the prescription painkiller OxyContin, touches on one of the country’s largest public health crises. Experts say the decision may also have important consequences for other cases that use the bankruptcy system to settle claims of mass injuries. Here’s what you need to know about the court’s decision:Why did the Supreme Court decide to weigh in? It’s rare for the Supreme Court to agree to hear a bankruptcy court dispute, experts say, especially one dealing with a settlement agreement in a mass-injury case. Trustee Program, a watchdog office within the Justice Department, that petitioned the Supreme Court to review the deal.

Persons: Sackler Organizations: Supreme, Purdue Pharma, Purdue, U.S ., Justice Department Locations: U.S

☆ Supreme Court Pauses Opioid Settlement With Sacklers Pending Review
▼ + stars: | 2023-08-10 | by ( Abbie Vansickle | More About Abbie Vansickle | ) www.nytimes.com time to read: +1 min

The Supreme Court agreed on Thursday to consider the government’s challenge of a bankruptcy settlement involving Purdue Pharma, putting on pause a deal that would have shielded members of the wealthy Sackler family from civil opioid lawsuits in exchange for payments of up to $6 billion to thousands of plaintiffs. In doing so, the court sided with the Justice Department, which had requested the court put the settlement plan on hold while it considered reviewing the agreement. The government has argued that the family behind Purdue Pharma, maker of the prescription painkiller OxyContin, should not be able to take advantage of legal protections meant for debtors in “financial distress.”The court’s order, which was unsigned, gave no reasons and included no public dissents, adds to the uncertainty around the plan to compensate states, local governments, tribes and individuals harmed by the opioid crisis while offering protection for the Sackler family. The order specified that the justices would hear arguments in the case in December. The court’s decision to take up the challenge to the bankruptcy agreement is the latest twist in the yearslong legal battle over compensation for victims of the prescription drug crisis.

Persons: Sackler Organizations: Purdue Pharma, Justice Department

REUTERS/George Frey/File PhotoNEW YORK, Aug 4 (Reuters) - Oxycontin maker Purdue Pharma on Friday asked the U.S. Supreme Court to reject the U.S. Department of Justice's request to delay its multi-billion-dollar bankruptcy settlement resolving thousands of lawsuits against it over the opioid epidemic. The department's bankruptcy watchdog last week asked the Supreme Court to pause the settlement, which would shield the company's Sackler family owners from opioid lawsuits in exchange for a $6 billion contribution to a broader settlement with states, local governments and victims of addiction. The Department of Justice (DOJ) asked the high court to put the deal on hold after a federal appeals court rejected a proposed delay. That position was echoed by a group representing 60,000 people who have filed personal injury opioid claims in Purdue's bankruptcy. Similar lawsuits related to the U.S. opioid crisis have resulted in more than $50 billion in settlements with manufacturers, drug distributors and pharmacy chains.

Persons: George Frey, Sackler, Purdue's, OxyContin, Dietrich Knauth, Grant McCool Organizations: Purdue Pharma, REUTERS, U.S, Supreme, U.S . Department, of Justice, Purdue, Thomson Locations: Provo , Utah, U.S, Purdue's

NEW YORK, July 28 (Reuters) - The U.S. Department of Justice on Friday asked the U.S. Supreme Court to stop Purdue Pharma from proceeding with a bankruptcy settlement that protects its Sackler family owners from lawsuits. Purdue's bankruptcy plan would shield its owners from opioid lawsuits in exchange for a $6 billion contribution to the company's broader bankruptcy settlement. Approving Purdue's bankruptcy plan "would leave in place a roadmap for wealthy corporations and individuals to misuse the bankruptcy system," the U.S Trustee argued. They said in May that the bankruptcy settlement would provide "substantial resources for people and communities in need." The Supreme Court set an Aug. 4 deadline for Purdue to respond.

Persons: Sackler, OxyContin, Dietrich Knauth, Matthew Lewis Organizations: YORK, U.S . Department of Justice, U.S, Supreme, Purdue Pharma, Purdue, U.S . Trustee, The U.S, Thomson Locations: Purdue's, U.S, Connecticut, New York

☆ An Appeals Court Gave the Sacklers Legal Immunity. Here’s What the Ruling Means.
▼ + stars: | 2023-05-31 | by ( Jan Hoffman | ) www.nytimes.com time to read: +1 min

In exchange, they have agreed to make payments of up to $6 billion to thousands of plaintiffs in now-suspended lawsuits. The ruling was part of a court review of a bankruptcy restructuring plan for Purdue, which filed for Chapter 11 protection in September 2019. Companies in bankruptcy customarily get protection from legal claims; owners who have not filed for personal bankruptcy usually do not. When the company filed for bankruptcy, the Sacklers faced about 400 lawsuits over their role in Purdue’s opioid business. Legal experts say that the ruling, by the United States Court of Appeals for the Second Circuit, has implications for the Purdue case specifically and for owners of companies seeking bankruptcy generally.

Persons: Sackler Organizations: Purdue Pharma, Purdue, Companies, United States, Appeals, Second Circuit

WASHINGTON, Dec 29 (Reuters) - The U.S. government on Thursday filed a lawsuit accusing AmerisourceBergen Corp (ABC.N), one of the nation's largest drug distributors, of helping ignite the nation's deadly opioid epidemic by failing to report hundreds of thousands of suspicious orders of prescription painkillers. The government said AmerisourceBergen had since 2014 systematically refused or negligently failed to flag suspicious orders by pharmacy customers when it had reason to know that opioids were being diverted to illegal channels. "For years, AmerisourceBergen prioritized profits over its legal obligations and over Americans' well-being," Associate Attorney General Vanita Gupta told reporters. In a statement, AmerisourceBergen called the lawsuit an improper attempt to "shift blame" and the burdens of law enforcement from the Justice Department and DEA to the companies they regulate. The Justice Department said AmerisourceBergen for years understaffed and unfunded programs designed to ensure compliance with the Controlled Substances Act.

Search resuls for: "painkiller OxyContin"

15 mentions found